Pfizer terminates license to three products with Acura Pharmaceuticals
The three products all used Acura's AVERSION Technology, and they will return to Acura, said termination becoming effective in 12 months under the terms of Acura’s license agreement with a subsidiary of Pfizer
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
About the Author
- This person does not yet have a bio.
Related Topics
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discover how supercritical fluids expand chromatographic capabilities across diverse analytical challenges.
Evolving approaches to conjugation chemistry and linker–payload design are helping address persistent challenges in bioconjugate development.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.
